Search Results for "insulin lispro"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for insulin lispro. Results 1 to 2 of 2 total matches.
See also: Humalog

Lyumjev - A New Insulin Lispro for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
Lyumjev - A New Insulin Lispro for Diabetes ...
The FDA has approved insulin lispro-aabc (Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog), for treatment of type 1 and type 2 diabetes in adults. Fiasp, a faster-acting formulation of insulin aspart (Novolog), was approved in 2017.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):162-3 |  Show IntroductionHide Introduction

In Brief: Semglee - A New Insulin Glargine for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
to receive once-daily treatment with Semglee or Lantus in addition to mealtime insulin lispro. In both ...
The FDA has approved Semglee (Mylan), an insulin glargine product similar to Lantus, for treatment of type 1 diabetes in children and adults and type 2 diabetes in adults. Semglee is the second "follow-on" insulin glargine product to become available in the US; Basaglar, which is also similar to Lantus, was the first. Lantus is a recombinant analog of human insulin that forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours with no pronounced peak effect.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):14-5 |  Show IntroductionHide Introduction